Elevated Liver Enzymes (ELE) often present a diagnostic challenge for clinicians due to the myriad of potential causes. This brief review aims to provide a comprehensive approach to the diagnosis and management of ELE.
Diagnosis of ELE begins with a thorough history and physical examination. Key factors to consider include alcohol consumption, medication use, and exposure to hepatotoxic substances. Laboratory investigations should include a complete liver panel, coagulation studies, and serologic tests for viral hepatitis.
Management of ELE primarily focuses on addressing the underlying cause. This may involve lifestyle modifications, medication changes, or specific treatments for identified liver diseases. Close monitoring of liver function tests is essential to assess response to treatment and detect any potential complications.
Imaging studies, such as ultrasound or CT scan, can provide valuable information about the liver's structure and help identify conditions such as fatty liver disease or cirrhosis. However, these should be reserved for cases where initial investigations are inconclusive.
Diagnosing and managing ELE requires a systematic approach that includes thorough history taking, appropriate laboratory and imaging investigations, and targeted treatment strategies. By adopting such an approach, clinicians can effectively manage this common clinical dilemma.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation